Cytokinetics (NASDAQ: CYTK) net income
Cytokinetics reported a net loss of $785.0m for fiscal 2025; in fiscal 2024 it reported a net loss of $589.5m. Earnings per share were −$6.54.
Cytokinetics's best year of the last 10 was fiscal 2016. It reported a loss in 9 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$785.0m | — | −891.6% | −$6.54 |
| 2024 | −$589.5m | — | −3,191.1% | −$5.26 |
| 2023 | −$526.2m | — | −6,988.6% | −$5.45 |
| 2022 | −$389.0m | — | −411.2% | −$4.33 |
| 2021 | −$215.3m | — | −305.7% | −$2.80 |
| 2020 | −$127.3m | — | −228.0% | −$1.97 |
| 2019 | −$121.7m | — | −452.9% | — |
| 2018 | −$106.3m | — | −337.4% | — |
| 2017 | −$127.8m | −876.7% | −955.9% | −$2.59 |
| 2016 | $16.5m | — | 15.5% | $0.41 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Cytokinetics net income compared with its sector
By net income for its latest fiscal year, Cytokinetics ranks 488th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Cytokinetics, −891.6%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 486th | Biohaven | −$738.8m | — |
| 487th | Vaxcyte | −$766.6m | — |
| 488th | Cytokinetics | −$785.0m | −891.6% |
| 489th | Teleflex | −$905.6m | −45.4% |
| 490th | Baxter International | −$957.0m | −8.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Cytokinetics
- How much did Cytokinetics earn in fiscal 2025?
- Cytokinetics reported a net loss of $785.0m for fiscal 2025. In fiscal 2024 it reported a net loss of $589.5m.
- What are the earnings per share of Cytokinetics?
- They were −$6.54 in fiscal 2025, compared with −$5.26 in fiscal 2024.
- What was the most profitable year for Cytokinetics?
- Of its last 10 fiscal years, fiscal 2016, with $16.5m.
- Where does Cytokinetics rank in its sector by net income?
- It ranks 488th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Cytokinetics come from?
- From the annual report (Form 10-K) that Cytokinetics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Cytokinetics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Cytokinetics: the Cytokinetics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.